Compare Expensify Inc (EXFY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Zimmer Biomet Holdings Inc — how do they compare? Expensify Inc trades at $2.4 (market cap $208.82M), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 81.2× Expensify Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Expensify Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| EXFY | ZBH | |
|---|---|---|
Market Cap | $208.82M | $16.95B |
Volume | 456,102 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $2.72 | $103.98 |
52-Week Low | $0.75 | $79.58 |
Typical Hold Time | 41 Days | 89 Days |
Enterprise Value | $148.44M | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.30, up 1.32% today, showing technical bullish momentum with positive moving average signals. The company reported mixed Q2 2026 results with revenue of $33.9M and improved profitability, beating EPS estimates. Recent developments include AI-native ERP integrations and European card expansion, though fundamentals show negative net margins and high P/E ratio of 258.82. Analyst consensus is bullish with a $13.75 price target, representing significant upside potential from current levels.
EXFY presents a high-risk, high-reward opportunity with strong analyst optimism contrasting with fundamental challenges. The stock's substantial discount to consensus target offers potential upside, but investors must weigh improving cash flow trends against persistent negative profitability and competitive pressures in the expense management sector.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
